欢迎来到天天文库
浏览记录
ID:53272123
大小:274.91 KB
页数:3页
时间:2020-04-17
《不同剂量阿法骨化醇治疗IgA肾病的临床观察.pdf》由会员上传分享,免费在线阅读,更多相关内容在应用文档-天天文库。
1、不同剂量阿法骨化醇治疗IgA肾病的临床观察李六生,刘兰香,谢希,闫志群(三峡大学人民医院/宜昌市第一人民医院肾内科,湖北宜昌443000)中图分类号R692.3文献标志码A文章编号1001.0408(2014)36—3407—03DOI10.6039/j.issn.1001-0408.2014.36.12摘要目的:观察不同剂量阿法骨化醇治疗lea肾病(1eaN)的临床疗效和安全性。方法:将62例IgAN患者按随机数字表法均分为对照组和观察组。两组患者均给予低盐、低脂、低蛋白饮食,维持原有肾素血管紧张素系统(RAs)阻滞药双倍剂量不变等常规治疗。在此基础上,对
2、照组患者给予阿法骨化醇胶丸0.25,口服,qd;观察组患者给予阿法骨化醇胶丸O.5gg,口服,qd。合并高血压患者在血压不迭标的情况下加服长效钙离子拮抗药控制血压。两组患者疗程均为l2周。观察两组患者临床疗效,治疗前后血清胱抑素c(Cys—C)、血尿素氮(BUN)、血肌酐(Scr)、血钙(Ca)、血磷(P)、血全段甲状旁腺激素(iPTH)、24小时尿蛋白定量(24hUTP)、平均动脉压(MAP)及不良反应发生情况。结果:治疗后观察组患者总有效率显著高于对照组,Cys.C、24hUTP均显著低于对照组,差异有统计学意义(P3、Scr、Ca、P、iPTH、MAP比较,差异均无统计学意义(尸>0.O5)。两组患者治疗期间均未见明显不良反应发生。结论:大剂量阿法骨化醇可更有效地降低IgAN患者尿蛋白水平、保护肾功能,且安全性较好。关键词IgA肾病;蛋白尿;阿法骨化醇;疗效;安全性ClinicalObservationofDifferentDosesofAlfacalcidolintheTreatmentofIgANephropathyLILiu—sheng,LIULan-xiang,XIEXi,YANZhi-qun(Dept.ofNephrology,ThreeGorgesUniver4、sityPeople’sHospital/YichangFirstPeople’sHospital,HubeiYichang443000,China)ABSTRACTOBJECTIVE:ToobservetheclinicaleficacyandsafetyofdiferentdosageofalfacalcidolinthetreatmentofIgAnephropathy(IgAN).METHODS:62patientswithIgANwererandomlydividedintocontrolgroupandobservationgroup.Bothg5、roupsweregivenlow—salt,low—lipidandhigh—qualitylow—proteindiet,andmaintainedpreviousconventionaltreatmentasdoubledoseofRASblock,etc.Onthisbasis,controlgroupwasadditionalgivenAlfacalcidolcapsule0.25ugorallyonceaday;observa.tiongroupwasadditionalgivenAlfacalcidolcapsule0.5ugorallyonc6、eaday.IgANpatientswithhypertensionweregivenlong—act-ingcalciumantagonistwhenthebloodpressurewasnotuptothestandard.Treatmentcourseof2groupslastedfor12weeks.Clini—caleficacy,Cys-C,BUN,Scr,Ca,P,iPTH,24hhUTP,MAPandADRwereobservedin2groupsbe:foreandaftertreatment.RESULS:Thetomleffective7、rateofobservationgroupwassignificantlyhigherthanthatofcontrolgroup:Cys.Cand24hUTPof2groupsaftertreatment;therewasstatisticalsignificance(P0.05).NoobviousADRwasobservedin2groups.CONCLUSIoNS:Largedose8、ofalfaca1.cidolcanefective
3、Scr、Ca、P、iPTH、MAP比较,差异均无统计学意义(尸>0.O5)。两组患者治疗期间均未见明显不良反应发生。结论:大剂量阿法骨化醇可更有效地降低IgAN患者尿蛋白水平、保护肾功能,且安全性较好。关键词IgA肾病;蛋白尿;阿法骨化醇;疗效;安全性ClinicalObservationofDifferentDosesofAlfacalcidolintheTreatmentofIgANephropathyLILiu—sheng,LIULan-xiang,XIEXi,YANZhi-qun(Dept.ofNephrology,ThreeGorgesUniver
4、sityPeople’sHospital/YichangFirstPeople’sHospital,HubeiYichang443000,China)ABSTRACTOBJECTIVE:ToobservetheclinicaleficacyandsafetyofdiferentdosageofalfacalcidolinthetreatmentofIgAnephropathy(IgAN).METHODS:62patientswithIgANwererandomlydividedintocontrolgroupandobservationgroup.Bothg
5、roupsweregivenlow—salt,low—lipidandhigh—qualitylow—proteindiet,andmaintainedpreviousconventionaltreatmentasdoubledoseofRASblock,etc.Onthisbasis,controlgroupwasadditionalgivenAlfacalcidolcapsule0.25ugorallyonceaday;observa.tiongroupwasadditionalgivenAlfacalcidolcapsule0.5ugorallyonc
6、eaday.IgANpatientswithhypertensionweregivenlong—act-ingcalciumantagonistwhenthebloodpressurewasnotuptothestandard.Treatmentcourseof2groupslastedfor12weeks.Clini—caleficacy,Cys-C,BUN,Scr,Ca,P,iPTH,24hhUTP,MAPandADRwereobservedin2groupsbe:foreandaftertreatment.RESULS:Thetomleffective
7、rateofobservationgroupwassignificantlyhigherthanthatofcontrolgroup:Cys.Cand24hUTPof2groupsaftertreatment;therewasstatisticalsignificance(P0.05).NoobviousADRwasobservedin2groups.CONCLUSIoNS:Largedose
8、ofalfaca1.cidolcanefective
此文档下载收益归作者所有